(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

CONJUGADOS DE FÁRMACO-ANTICORPO ANTI-DLL3 E MÉTODOS DE UTILIZAÇÃO

ArquivadaInvention PatentPCT · US2016047870

Application data

Number

112018003269

Type

Invention Patent

Filing

08/19/2016

Publication

09/25/2018

PCT

US2016047870

Progress at the INPI

  1. Filing08/19/16
  2. Publication09/25/18
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 08/19/2016 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 11/19/2019. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

ABBVIE STEMCENTRX LLC

US

See this company's full portfolio

Inventors

B. S. (pessoa física)

US

H. K. (pessoa física)

US

J. P. (pessoa física)

US

S. D. (pessoa física)

US

T. H. (pessoa física)

US

W. A. (pessoa física)

US

Technical data

Priority claims

US

62/207,830 · 08/20/2015

US

62/323,998 · 04/18/2016

US

62/373,906 · 08/11/2016

Abstract

São fornecidos novos anticorpos anti-DLL3 e conjugados de fármaco-anticorpo, e métodos de utilização de tais anticorpos anti-DLL3 e conjugados de fármaco-anticorpo para tratar câncer.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

11/19/2019

RPI 2550

Arquivamento - Art. 33 da LPI

#11.1

09/03/2019

RPI 2539

Notificação de entrada na fase nacional - PCT

#1.3

09/25/2018

RPI 2490

Alteração de dados cadastrais

#1.1

04/03/2018

RPI 2465

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.